VERTEX PHARMACEUTICALS INC / MA Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 447.00K shares, a 24.17% increase from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 360.00K shares, a 40.20% decline from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 602.00K shares, a 44.62% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 1.09M shares, a 109.85% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 447.00K shares 10-K · filed 2026-02-13 | |
| 2024-12-31 | 360.00K shares 10-K · filed 2025-02-13 | |
| 2023-12-31 | 602.00K shares 10-K · filed 2024-02-15 | |
| 2022-12-31 | 1.09M shares 10-K · filed 2023-02-10 | |
| 2021-12-31 | 518.00K shares 10-K · filed 2022-02-09 | |
| 2020-12-31 | 1.88M shares 10-K · filed 2021-02-11 | |
| 2019-12-31 | 3.33M shares 10-K · filed 2020-02-13 | |
| 2018-12-31 | 3.08M shares 10-K · filed 2019-02-13 | |
| 2017-12-31 | 4.56M shares 10-K · filed 2018-02-15 | |
| 2016-12-31 | 1.06M shares 10-K · filed 2017-02-23 | |
| 2015-12-31 | 3.29M shares 10-K · filed 2016-02-16 | |
| 2014-12-31 | 6.15M shares 10-K · filed 2015-02-13 | |
| 2013-12-31 | 7.00M shares 10-K · filed 2014-02-11 | |
| 2012-12-31 | 5.86M shares 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |